Go back

Chemotherapy Induced Peripheral Neuropathy (CIPN): Precision Medicine: Biomarkers and Risk Prediction in Chemotherapy Induced Peripheral Neuropathy

24m 41s

Chemotherapy Induced Peripheral Neuropathy (CIPN): Precision Medicine: Biomarkers and Risk Prediction in Chemotherapy Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy (CIPN) remains a complex and challenging side effect of cancer treatment, with significant variability in patient susceptibility. Professor Rosa Velascu outlines a comprehensive approach to identifying risk through multiple biomarker types—clinical symptoms, neurophysiological assessments, blood-based markers like neurofilament light chain (NFL), and imaging data. While no single marker is currently sufficient for reliable prediction, early clinical signs, such as acute oxaliplatin or taxane reactions, and objective blood tests like NFL show strong potential for early detection of axonal injury. NFL levels rise during treatment and correlate with neuropathy severity, particularly with oxaliplatin, though its response varies by drug class. Genetic risk factors remain limited due to phenotypic heterogeneity, small study sizes, and inconsistent definitions. The most promising future direction is a dynamic, drug-specific risk prediction algorithm that integrates baseline clinical risk, genetics, real-time biomarkers, and evolving treatment exposure. Such models must be validated in large, prospective cohorts and designed for clinical actionability—supporting early intervention and personalized therapy without compromising oncologic outcomes. Ultimately, success depends on interdisciplinary collaboration between oncologists and neurologists to develop practical, biologically meaningful tools that improve patient outcomes and quality of life.

Transcription

3187 Words, 20691 Characters

English
[MUSIC] Welcome to the Parishlanab Podcast, the official podcast of the Parishlanab Society. Exploring topics in Parishlanab Resorters, Awareness, Education and Advocacy. We are your hosts, Dr. Paola Alberti from University of Milano, Bicocca, Italy, and Fessings to Zennepark from University of Sydney, Australia. Welcome to the next episode in the peripheral nerve podcast series, "Understanding Chemotherapy and Juice peripheral neuropathy". In this episode, we are delighted to welcome Professor Rosa Velascu, Professor Velascu is a neurologist and principal investigator at the Neuroncology Group of the Catalan Institute of oncology at Belvich University Hospital in Barcelona and an adjunct professor at University Talk, Autónoma de Barcelona. Today, we are excited to discuss the topic of precision medicine in the IPN, exploring our biomarkers may assist in predicting risk of these disease. Professor Velascu's research work is focused on neurotoxicity, spanning the spectrum of clinical studies, biolarka discovery, and guideline development. She's made major contributions to the study of neurological complications following chemotherapy, as well as emerging cancer therapies such as amino therapy and Carti cell therapy. Her work integrates serum biomarkers, neurophysiology, and risk faster assessment to advance personalized approaches to mitigate neurotoxicity. Today, we're excited to discuss the search for sensitive biomarkers to define why some patients develop toxicity and others do not, following neurotoxic chemotherapy, or honor to have you here speaking with us today. Like a professor Velascu, it's so wonderful to have you here with us today. Thank you, Paola, and Susanna for the invitation, and we're happy to be here to share my knowledge and to enjoy this focus. Thank you so much. If I can start with the first question, can you provide an overview of key biomarkers relevant to predicted monitors here, including genetics, proteomic, metabolomic, or electrophysiological? Yes, of course. When discussing biomarkers in CypN, I usually find it helpful to separate them into four groups, clinical, neurophysiological, block-based, and imaging biomarkers. And technical markers and risk factors include redomboaids, diabetes, practicing neuropathy, comorbidities, or previous exposure to neurotoxic chemotherapy. And these factors are in form because they help us understand the patient's baseline vulnerability. However, we have seen that most of them are not as strong enough on their own to predict severe CypN in individual patients. So they are more useful as part of the general risk profile than as isolated predictors. It probably there are also early clinical symptoms or in treatment that can be very informative, in patient receiving oxaliplatine. A key neurotoxicity is a good example that these patients may develop called ingesthesia, cramps, or vesicles shortly after infusion, and these symptoms are often transient, but they are not irrelevant. severe prolonged acute oxaliplatine neurotoxicity can identify patients at higher risk of chronic oxaliplatine neuropathy later in the course of treatment, for example. But similarly, in patients with faculty tax cell and acute pain syndrome, maybe informative. And it usually appears within the first days of treatment with muscle and joint pain that picks around the three and then improves. And patients with more intense symptoms, we know that they will be more likely to develop persistent sensory neuropathy. So chronic clinical symptoms are not only adverse effects, they may also contain predictive information. The second route is new physiological biomarkers, and nerve conduction studies can detect subclinical nerve damage before symptoms are obvious. And the typical pattern in CIPN is a reduction in sensory nerve action potentials with relatively preserved motor responses, which is consistent with predominantly sensory axonal neuropathy. This is particularly useful in oxaliplatine induced neuropathy, where longitudinal studies have shown that early changes in sensory nerves, especially the dorsal subtle and radial nerves, and help predict neurological outcome after at the end of treatment. But their limitation, however, is practical and nerve conduction studies require a clean mind, training personnel, and ideally baseline measurements for comparison. So they are informative, but they are not always easy to implement in a routine oncology practice, especially if we want to monitor large number of patients repeatedly. The third group is blood-based biomarkers, and genetic markers having wireless floor, but today, no genetic marker is thoroughly validated for clinical use, and other candidates include NSL or neurotrophic factors such as NGF or BDNF, because they may re-slend nerve injury or reduce regenerative capacity of the nerve. And also, my metabolism can meet the convalescent markers can be interesting, because my convalescent functions and oxidative stress are central mechanisms in CIPN. And finally, I would like to talk about imaging biomarkers, and high-resolutional dorsal and magnetic resonance neuropathy can show structural changes in peripheral nerves, but thus, and availability, they meet their routine use, though. However, a very interesting and more accessible approach is the use of protein-city scans to assess body composition, particularly circopenia. And this is relevant, because many contributions already undergo city scans as part of their oncology there, so we can potentially reduce existing images to extract additional information about skeletal muscle mass. Circopenia may influence chemotherapy toxicity, because a standard chemotherapy dosing is usually based on body surface areas, using height and weight, but this does not capture body composition. For example, two patients may have the same body weight or BMI, but very different muscle mass, which may affect the pharmacokinetics of antineoplastic agents. So in our racing war, for example, we have already evaluated these regimen circopenia, and we identified that it was associated with the development of clinically relevant CIPN. The main finding of our war was that between the circopenia was associated with 2.4 to 1.5, all higher odds of clinically relevant CIPN. And to sum up, I would like to say that today, no single biomarker will probably be enough. Thank you so much, Rosen, for that great overview. Really, a very useful insight to understand a bit better the world of biomarkers, and stemming out from this reasoning. In your opinion, what is limited in the past over ability to identify and validate genetic risk factors to predict the development of CIPN? I would say that one of the male mutations has been that CIPN represent a complex phenotype. We often use the term chemo-serpent use for neuropathy in a general way, but in reality neuropathy induced by pachytaxyl, oxaliplatin, or vortusomy, may not represent exactly the same biological process. These drugs affect the birth of other systems to different mechanisms, with different time being different reversility and different clinical patterns. So that is already a challenge for genetics. If we mix different drugs, tumor types, doses, and scandals in the same analysis, the genetics sign all becomes diluted. Then a variant that might be irrelevant for toxicity may not necessarily be relevant for oxaliplatin in this neurotoxicity. So one of the lessons, in my opinion, from the field, is that we need to be much more drug-specific when we study genetic risk. And the second implementation has been powdered neuropathy phenotype is defined. Human studies have used patient-reported symptoms, other used clinical-weight toxicity scales, neurological examination, or nerve conduction studies. So these are all valuable measures, but they are gut-equivalent. If the outcome is not harmonized, even the real genetic association may be difficult to reproduce. And it is why many pharmacogenetic findings in CIPN have been inconsistent. The studies also had methodological limitations, heterogeneous definitions of CIPN, and assessment tools that were not always sufficiently reproducible. And also there is an issue of statistical power, for most common genetic variants, the effect of a single polymorphism is usually modest. So we need large cohorts and independent rebukation. In CIPN, many studies have been relatively small, exploratory, or raised on candidate chains. And this increases the resistance. false positive findings and makes it difficult to know whether a signal is real or is generally related to the specific population studied. We also have many confunding factors like comorbidities, age, drug factors with ten influence, the risk of neuropathy, and if these are not carefully controlled, they can blur the interpretation of genetic data. So all those several candidate variants can be proposed, including variants in gen related to eye channels, neuronal receptors, and metabolic pathways. As you know, a specific polymorphism has been validated enough to be routinely to predict CFP and clinical practice. And to conclude, for me, the future of genetics and CFP and it's not to look for one variant in isolation, it's to integrate genetic data into larger better phenotype at drug-specific cohorts, and then combine genetics with clinical receptors and other biomarkers. Thank you so much for this clear cut to review. Thank you. You mentioned earlier about neurosurlement light chain as a potential biomarker in CIPN. Can you discuss a bit about the potential utility of NFL in CIPN, including the differences between different chemotherapy classes? Yes, of course. Yeah, and neurosurlement light chain, or NFL, is a very interesting biomarker in CIPN because it gives us a biological sign-up of neuro-axonal injury. And this hits very well with what we know about chemotherapy because CIPN is maybe an axonal neuropathy. One practical advantage is that contributions already have regular blood tests during chemotherapy. So adding a biomarker, such as NFL, would be relatively easy compared with other techniques. So it could not require a complex or invasive procedure, and it could be repeated over time. This is important because CIPN is a dynamic process, and we do not only want to know whether neuropathy is present at one single time point, we want to understand whether nerve damage is progressing, stabilizing, or recovering. So the potential utility of NFL is that it could provide a more objective measure of neurodomage, complementing what we do obtain from symptoms, neurological examination, clinical skills, or neuro-conditioning studies. And this is a relevant because in current practice, we often react when the patient already reports symptoms, such as numbness, tingling pain, or functional impairment. But at that point, some degree of nerve injury may already be established. So a blunt biomarker could help us detect ongoing axonal injury earlier and in a more objective way. The recent mask narrative review identified 11 technical studies mostly conducted in women with breast cancer, suggesting that, as a serum near filaments, tend to rise during treatment with neurotoxic chemotherapy and that partly increases often after the first few cycles or after two or three doses only, may be associated with later CIPN similarity. In fact, in our studies, we have seen that NFL levels increase during treatment with neurotoxic chemotherapy and then this increase correlates with the severity of neuropathy and with neurophysiological abnormalities. For example, in patients who did with witty peptidaxyl, thyrin, NFL levels were associated with more CIPN or peptidaxyl induced spray from neuropathy. And we also observed that early imprisonment in NNSL after the first week's self-treatment would help identify patients at higher risk of developing clinical or relevant neuropathy later on. So this doesn't mean that NFL should replace clinical evaluation and I think this is an important point. NFL is not a biomarker of symptoms or pain specifically. It is a biomarker of axonal injury. So if a patient has neuropathic pain, NFL may not tell us the whole story or the pain phenotype. It tells us more about whether there is an online structural nerve damage. And for that reason, it should complement the patient's symptoms and neurological examination or even neurophysiology when you do it. Another key point about NFL is that doesn't behave exactly the same across all chemotherapy classes. That same, such as peptidaxyl, may produce relatively early and marketing increases in the NFL probably reflecting axonal injury during treatment. However, platinum compounds such as oxalicatin or cisplatin may show a different temper of profile. In our recent work, we also observed that NFL rises during treatment and tends to decline during recovery, but the magnitude and timing of these changes deferred among Asians. So this means that the future clinical use of NFL probably will not be based on one universal threshold for all patients and all drugs. More likely, we will need drug-specific cutouts, longitudinal measurements at the specific time points and interpretation according to each baseline NFL levels, treatment exposure and clinical context. So in summary, I see NFL as a very attractive biomarker because it's blood-based, objective, and repeatable. It could help us monitor near-toxicity more precisely and possibly detect axonal injury before neuropathy becomes severe. But it should be integrated into a broader clinical framework not used as a stand-alone decision tool. Fantastic, thank you so much. A very specific insight that inspired me. And considering all the opportunities and pitfalls that you mentioned, do you think that there is prospect for a novel risk prediction algorithm for CIPN, incorporating clinical risk factors, genetic markers, and other biomarkers in your opinion? Yes, I just think there is a real feature for risk prediction algorithms in CIPN. They could help us identify vulnerable patients earlier, monitor near-toxicity more objectively and personalize treatment before nerve damage because CIPNs are reversible. But they could be cautious about expecting one tempoli universal model that works for every patient and every chemotherapy agent. In my opinion, the future is probably not one general learning, but for said pain as a whole, but rather, drug-specific are drop-adapted prediction models. This is because, I said, actually, that celloccipitalia, vein crescine, or other neurotoxic agents can all cause neuropathy, but mechanisms and timing, I said, are not the same. And this is important to be keep in mind. I think that the models should integrate several layers of information. First, we have the baseline clinical risk profile, like age, or persistent neuropathy, or even not body composition, such as circopenia. And these factors may not be sufficient or not alone, but it helps to define the patient's baseline vulnerability. Ideally, genetic predators should also be included if available. In fact, in oncology, we already have examples where pharmacogenetics can guide treatment decisions such as the PYD variants for open-medium toxicity, and having something similar for said pain could be extremely valuable. Importantly, the algorithm should also include treatment-related variables, particularly the specific chemotherapy, and the cumulative dose and those intensity. And these are essential, because neurotoxicity is strongly influenced by drug exposure. And third, we should also include early warnings, same signs, during treatment. Some of these are clinical, such as acute oxaliplatin, or pactyltexyl neurotoxicity. Others could be biological or neurophysiology, enough connection studies for adults. There is a series where blood biomarkers, such as NFL, become especially interesting, because they could provide a practical and objective signal of ongoing axonal injury in real time. Because in my view, the most useful algorithm should not be static score calculated only with four chemotherapy starts. It should be dynamic, and updated during treatment, as new information becomes available. Same terms, functional impact, NFL changes, and of course, I know that I know this is not following the realistic yet, but several groups are on the wall and are working a collaborative way together to identify the different elements that could eventually lead to an ideal, predictive model for using clinical practice. Obviously, these models will need to be prospectively validated, adapted to each chemotherapy class, and designed to support Pindical Judgment. but not to replace it. This is important. Thank you so much. I totally agree with you and this could be the opportunity to start the collaboration and the study on this topic. Yes, of course. Thank you a little bit along this line. What do you think at the moment is the most promising avenue for future research in this field? For me, one of the most promising lines of research in CPN is the development of integrated and clinically useful prediction models. Of course, I do not think the featuring is about finding one perfect biomarker that will solve everything. It is more about combining different pieces of information and making them useful for real clinical decisions. Because CPN is complex and no single measurement captures the whole picture. That is why we need large, well-senotide, cohorts of concentrations fall with prospectively over time. And in my opinion, the question is not whether only one biomarker is associated with CPN. The real question is whether combining these markers can help us predict with a trace, monitor nerve damage during treatment and identify with a line to recover or develop persistent neuropathy. And an important point is that prediction should be aligned to the null. Based on risk, it's useful, but the patient's risk changes the treatment, as I've said, not, for example, the development of acute oxaliplatine neurotoxicity or rising in the cells, these changes should modify the risk estimate. So, future models should be dynamic, broader than fix it. And therefore, this studies should therefore assess patients before treatment during treatment and after treatment completion. And these could allow us to understand not only who develops CPN, but also who recovers, who develops persistent neuropathy and who is at risk of long-term functional impairment. And this is important because we must keep in mind that persistent CPN is not only a toxicity rate. It can affect walking, balance, menal dexterity, autonomy, sleep, quality of life, along, after-taxored treatment has ended. So, it's important to consider that we need to focus on clinical actionability. It's not enough to show that a biomarker is a statistically associated with neuropathy. The key question is whether it improves decision-making and ultimately benefits patients. So, this also, in my opinion, means that future research should involve both oncologists and neurologists. oncologists need tools that are practical and do not compromise cancer efficacy. And neurologists, we can help with accurate phenotyping, interpretation of neophysiology, and assessment of functional consequences. So, the real approach should be technically feasible, biologically meaningful, and useful for shared decision-making. To sum up, I would say that the most promising direction is a multimodal and tutorial and personalized approach to CIPN prediction. And the goal is to move from reacting once neuropathy is already established to identify vulnerable patients earlier and monitoring nerve damage treatment while still preserving the efficacy of cancer therapy. Thank you so much, Rosie. That was a fantastic answer and really outlined the need for collaboration across field in this space. Thank you, Professor Belasco, for sharing your insights. It was a pleasure to have you here as a guest today. Thank you for the invitation. You can find relevant papers in the show notes and visit [email protected] for more information about the peripheral net society. Thank you for listening. See you next month. The primary purpose of the peripheral nerve podcast is to meet the educational needs of its listeners and address practice gaps by providing practice oriented and scientifically-based education that will maintain an advanced competence and performance in the peripheral nerve field. A diversity of opinions exists in the medical field and the views of the podcast faculty do not represent those of the peripheral nerve society or constitute an endorsement by the peripheral nerve society.

Podcast Summary

Key Points:

  1. Biomarkers for chemotherapy-induced peripheral neuropathy (CIPN) can be categorized into clinical, neurophysiological, blood-based, and imaging types, with each offering unique insights.
  2. Early clinical symptoms like acute oxaliplatin or taxane-induced pain may predict later chronic neuropathy, providing valuable real-time warning signs.
  3. Nerve conduction studies detect subclinical sensory axonal damage, particularly in dorsal and radial nerves, but are limited by practicality and need for trained personnel.
  4. Neurofilament light chain (NFL) is a promising blood-based biomarker reflecting axonal injury, showing dynamic changes during treatment and correlating with neuropathy severity.
  5. NFL responses vary by chemotherapy class—oxaliplatin causes early increases, while platinum agents show delayed changes—indicating the need for drug-specific thresholds.
  6. Current genetic markers lack validation due to heterogeneous drug exposures, phenotypic definitions, and small study sizes, limiting reproducibility.
  7. A dynamic, drug-specific risk prediction algorithm integrating clinical risk, genetics, biomarkers (like NFL), and treatment exposure is a promising future direction.
  8. Future research must focus on multimodal, longitudinal models that improve clinical decision-making, track recovery, and reduce long-term disability from persistent CIPN.

Summary:

Chemotherapy-induced peripheral neuropathy (CIPN) remains a complex and challenging side effect of cancer treatment, with significant variability in patient susceptibility. Professor Rosa Velascu outlines a comprehensive approach to identifying risk through multiple biomarker types—clinical symptoms, neurophysiological assessments, blood-based markers like neurofilament light chain (NFL), and imaging data. While no single marker is currently sufficient for reliable prediction, early clinical signs, such as acute oxaliplatin or taxane reactions, and objective blood tests like NFL show strong potential for early detection of axonal injury.

NFL levels rise during treatment and correlate with neuropathy severity, particularly with oxaliplatin, though its response varies by drug class. Genetic risk factors remain limited due to phenotypic heterogeneity, small study sizes, and inconsistent definitions. The most promising future direction is a dynamic, drug-specific risk prediction algorithm that integrates baseline clinical risk, genetics, real-time biomarkers, and evolving treatment exposure.

Such models must be validated in large, prospective cohorts and designed for clinical actionability—supporting early intervention and personalized therapy without compromising oncologic outcomes. Ultimately, success depends on interdisciplinary collaboration between oncologists and neurologists to develop practical, biologically meaningful tools that improve patient outcomes and quality of life.

FAQs

Biomarkers are categorized into clinical, neurophysiological, blood-based, and imaging types. Clinical symptoms like acute pain or tingling can signal early risk. Nerve conduction studies detect subclinical nerve damage. Blood-based markers such as neurofilament light chain (NFL) indicate axonal injury. Imaging biomarkers like body composition scans can reveal circopenia linked to increased CIPN risk.

NFL is a blood-based biomarker that reflects axonal injury. It rises during neurotoxic chemotherapy and correlates with neuropathy severity. It can detect early nerve damage before symptoms appear, offering an objective, repeatable measure that complements clinical assessments.

No, different chemotherapies show distinct NFL profiles. Platinum agents like oxaliplatin may cause early and sustained increases, while others may show delayed rises or more gradual declines. Drug-specific thresholds and timing are needed for accurate interpretation.

CIPN is a complex, drug-specific condition with diverse mechanisms. Mixing different drugs, doses, and patient profiles dilutes genetic signals. Additionally, inconsistent phenotyping, small study sizes, and modest effect sizes of individual variants limit reliability and reproducibility.

Yes, early symptoms like acute oxaliplatin-induced pain or muscle/joint pain during treatment can predict the development of chronic neuropathy. More severe symptoms are associated with a higher likelihood of persistent sensory neuropathy.

Yes, dynamic, drug-specific algorithms combining clinical risk factors, genetics, and biomarkers like NFL show great promise. These models can help identify vulnerable patients early and personalize treatment to prevent or mitigate nerve damage.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.